Analysis of ResultsEPS of 6.9c was slightly better than estimates; sales of $10.8M was 6% better. EBITDA of $4.79M was 18% better. Revenue rose 15% (constant currency). EPS beat estimates even with higher R&D. Margins rose 3 points to 74%. The company discussed acquisitions and it has plenty of capacity for more deals in 2022. Cash remains high at ~$30M. The outlook is positive but no new formal guidance was provided.
Provided by 5iResearch (who love increasing margins). Clearly the markets are also impressed. GLTA